ClinicalTrials.gg
Not yet recruitingNCT07852234Updated Oct 1, 2026

Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome

A Phase 2 interventional study of Blinatumomab and background treatment in Primary Sjögren's Syndrome (pSS), sponsored by Beijing Tongren Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Beijing Tongren Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Planned enrollment
80th of 83
12 · median 80
Started
2026
with 10 others
Phase 2
6 of 106
2 open now
Primary completion
2027-10
later than 25 of 29 live
Registered
105th of 106
by date
Lead sponsor
8 of 106
Beijing Tongren Hospital

Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 80th largest by planned enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 25 of the 29 other live ones, and was the 105th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab. The main questions it aims to answer are:

Is low-dose blinatumomab more effective in patients with moderate-to-severe primary Sjögren's Syndrome who have an inadequate response or intolerance to conventional treatment? How does blinatumomab affect B cells, antibody levels, and the immune system in these participants?

Researchers will compare background treatment plus low-dose Blinatumomab with background treatment only to see if low-dose Blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome.

Participants will:

Receive background treatment for 24 weeks, including hydroxychloroquine 400 mg each day, methylprednisolone 8 mg each day, and sodium hyaluronate eye drops 4 times each day.

If assigned to the blinatumomab group, receive blinatumomab by continuous intravenous infusion for 5 days during week 1 and again for 5 days during week 3. The dose will be 9 micrograms per day.

Attend regular follow-up visits for clinical assessments, laboratory tests, and monitoring of treatment effectiveness and safety.

03

Conditions studied

  • Primary Sjögren's Syndrome (pSS)

Browse trials for

Keywords

  • Primary Sjögren's Syndrome
  • Blinatumomab for Injection
  • Dry eye disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who voluntarily agree to comply with the study protocol and provide written .
  2. Male or female participants aged 18 to 70 years.
  3. Diagnosis of primary Sjögren's syndrome according to the 2016 ACR/EULAR classification criteria.
  4. Positive anti-SSA antibody at screening.
  5. Moderate-to-severe active primary Sjögren's syndrome at screening, defined as an EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥5.
  6. Inadequate response or intolerance to conventional treatment, defined as having received at least one immunomodulatory therapy, including , cyclophosphamide, antimalarial drugs, azathioprine, or biologic agents, for more than 6 months before screening, with unsatisfactory disease control based on ESSDAI or other clinical assessments, or recurrence of active disease after an initial treatment response.
  7. Diagnosis of dry eye disease according to the 2024 Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Dry Eye.
  8. Moderate-to-severe dry eye disease at screening.
  9. Laboratory values meeting all of the following requirements:

    • Absolute lymphocyte count ≥0.5 × 10⁹/L
    • Peripheral blood CD19+ B-cell count ≥25 cells/µL
    • ≥1.0 × 10⁹/L
    • ≥8 g/dL
    • count ≥75 × 10⁹/L
    • Total ≤1.5 × (ULN), except for participants with confirmed Gilbert syndrome
    • (AST) and alanine aminotransferase (ALT) ≤2.0 × ULN
    • Estimated ≥30 mL/min/1.73 m², calculated using the CKD-EPI equation
  10. Both eyes will undergo study-related examinations and treatment.

Exclusion criteria

Exclusion Criteria:

  1. Secondary Sjögren's syndrome.
  2. Severe cardiovascular, hepatic, renal, respiratory, endocrine, or malignant disease, or uncontrolled acute or chronic infection.
  3. Active and severe central nervous system manifestations related to Sjögren's syndrome.
  4. History of stroke, epilepsy, dementia, Parkinson's disease, ataxia, cerebellar disease, psychosis, paresis, aphasia, or any other neurological condition that, in the investigator's judgment, may place the participant at excessive risk or interfere with study assessments.
  5. Active ocular infection.
  6. Other severe ocular diseases or ocular trauma diagnosed within 6 months before enrollment, including glaucoma, uveitis, retinal disease, chemical injury, or thermal burns.
  7. Ocular surgery, including cataract surgery, within 6 months before enrollment.
  8. Use of other eye drops that may affect the study outcomes.
  9. Participation in another interventional clinical study.
  10. Pregnancy or breastfeeding, or plans to become pregnant during the study period.
  11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Control group

    Participants will receive background treatment alone for 24 weeks and will not receive blinatumomab. The background treatment includes: (1) hydroxychloroquine, 400 mg/day; (2) methylprednisolone, 8 mg/day; and (3) sodium hyaluronate eye drops, 4 times/day.

    Drug: background treatment

  • Experimental
    Experimental group

    In addition to the same background treatment as the control group, participants will receive low-dose, short-course blinatumomab treatment in the Department of Rheumatology and Immunology. The dosing regimen is as follows: 1. First cycle: blinatumomab 9 μg/day by continuous intravenous infusion for 5 consecutive days, for a total dose of 45 μg. 2. Second cycle: the same dose and administration schedule will be repeated 1 week later.

    Drug: Blinatumomab · Drug: background treatment

Interventions

  • Participants will receive low-dose, short-course blinatumomab treatment. The dosing regimen is as follows: 1. First cycle: blinatumomab 9 μg/day by continuous intravenous infusion for 5 consecutive days, for a total dose of 45 μg. 2. Second cycle: the same dose and administration schedule will be repeated 1 week later.

  • Drugbackground treatment

    All the participants will receive background treatment for 24 weeks. The background treatment includes: (1) hydroxychloroquine, 400 mg/day; (2) methylprednisolone, 8 mg/day; and (3) sodium hyaluronate eye drops, 4 times/day.

06

What researchers measure

Primary outcomes

  1. NEI corneal fluorescein staining score

    Corneal epithelial damage will be assessed using the National Eye Institute (NEI) corneal fluorescein staining scale. Each cornea is divided into five regions, and each region is scored from 0 to 3. The total score ranges from 0 to 15, with higher scores indicating more severe corneal epithelial damage. The outcome is calculated as the Week 24 total score minus the baseline score. A decrease of 3 points or more from baseline is defined as a response.

    Time frame: Baseline and Week 24

  2. ESSDAI score

    Systemic disease activity will be assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). The ESSDAI evaluates disease activity across 12 organ or system domains and has a total score ranging from 0 to 123, with higher scores indicating greater disease activity. The outcome is calculated as the Week 24 total score minus the baseline score. A decrease of 3 points or more from baseline is defined as a response.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. NEI score at follow-up visits

    Corneal epithelial damage will be assessed using the National Eye Institute corneal fluorescein staining scale. The total score ranges from 0 to 15, with higher scores indicating more severe corneal epithelial damage. Changes from baseline will be assessed at each prespecified follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 20

  2. OSDI score

    Dry eye symptoms and their effects on visual function and quality of life will be assessed using the 12-item Ocular Surface Disease Index (OSDI). The total score ranges from 0 to 100, with higher scores indicating more severe symptoms and greater impairment. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  3. FBUT

    Tear film stability will be assessed using fluorescein tear film break-up time (FBUT). FBUT is measured in seconds from eye opening until the first break in the fluorescein-stained tear film is observed. Measurements will be repeated for each eye and averaged according to the study protocol. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  4. Schirmer I test

    Tear secretion will be assessed using the Schirmer I test without topical anesthesia. A standard filter paper strip is placed in the lower conjunctival sac, and the length of wetting is measured in millimeters after 5 minutes. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  5. NIBUT

    Tear film stability will be assessed using non-invasive tear film break-up time (NIBUT) measured with an ocular surface analyzer. The instrument records the time from completion of a blink to the first detected tear film break. Measurements are generally repeated three times and averaged. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  6. Tear meniscus height

    Tear secretion and distribution will be assessed by measuring lower tear meniscus height using an ocular surface analyzer. The upper and lower boundaries of the lower tear meniscus beneath the central pupil are identified, and tear meniscus height is calculated in millimeters. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  7. Tear film lipid layer thickness

    Tear film lipid layer thickness will be measured using an ocular surface analyzer to assess meibomian gland-related tear film function. Lipid layer thickness is quantified using interference color units, with 1 interference color unit corresponding to approximately 1 nm. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  8. Incomplete blink rate

    Blinking behavior will be assessed using an ocular surface analyzer. The incomplete blink rate is calculated as the number of incomplete blinks divided by the total number of blinks during the observation period and expressed as a percentage. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  9. ESSDAI at follow-up visits

    Systemic disease activity will be assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), which evaluates 12 organ or system domains. Higher scores indicate greater disease activity. Changes from baseline will be assessed at prespecified follow-up visits.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 20

  10. ESSPRI

    Patient-reported symptoms will be assessed using the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). The ESSPRI evaluates dryness, fatigue, and pain on 0-to-10 numeric rating scales. The total score is the average of the three domain scores, with higher scores indicating more severe symptoms. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  11. MFI-20

    Fatigue will be assessed using the 20-item Multidimensional Fatigue Inventory (MFI-20), which includes general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The total score ranges from 20 to 100, with higher scores indicating greater fatigue. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  12. Unstimulated salivary flow rate

    Salivary gland function will be assessed by measuring unstimulated whole salivary flow. Participants will collect saliva at rest for 15 minutes, and the salivary flow rate will be calculated in milliliters per minute. Changes from baseline will be assessed at each follow-up visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24

  13. Autoantibody titers

    Serum autoantibodies, including anti-SSA/Ro, anti-SSB/La, anti-dsDNA, anti-Sm, anti-RNP, antinuclear antibodies (ANA), and antineutrophil cytoplasmic antibodies (ANCA), will be measured. Changes in antibody titers from baseline will be assessed. The proportion of participants whose antibody status changes from positive to negative will also be evaluated.

    Time frame: Baseline and Weeks 4, 12, and 24

  14. Immunoglobulin levels

    Serum immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) concentrations will be measured to assess changes in humoral immune status. Changes from baseline will be evaluated, with particular attention to changes in IgG levels.

    Time frame: Baseline and Weeks 2, 4, 12, and 24

  15. Peripheral blood lymphocyte subsets

    Peripheral blood lymphocyte subsets will be assessed by flow cytometry. Absolute counts of lymphocyte subsets and detailed B-cell subsets will be measured to evaluate the effects of treatment on B cells and T cells.

    Time frame: Baseline and Weeks 2, 4, 12, and 24

  16. BCR/TCR repertoire

    B-cell receptor (BCR) and T-cell receptor (TCR) repertoires will be assessed by high-throughput sequencing of lymphocytes isolated from peripheral blood. Changes in immune repertoire characteristics at follow-up visits will be compared with baseline as an exploratory assessment of treatment effects on adaptive immunity.

    Time frame: Baseline and Weeks 4, 12, and 24

  17. Adverse events

    Safety will be assessed by recording adverse events (AEs), serious adverse events (SAEs), adverse events leading to treatment discontinuation, clinically significant laboratory abnormalities, electrocardiogram abnormalities, and changes in vital signs. Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: From baseline through Week 24

07

Study locations

1 site
  • Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2027, 12 months later.

Of 91 phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 12. This study's planned 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Sep 25, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852234
Responsible party
Jinyuan,MD (President of Beijing Tongren Hospital, Chief Physician of Ophthalmology Department, Beijing Tongren Hospital) — Principal investigator
First posted
Oct 1, 2026
Start date
Sep 25, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Bowen Wang, PhD
Contact
sysuwangbowen@126.com
+86 15989006980

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion